{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lu X"],"funding":["CAMS Innovation Fund for Medical Science","Beijing Research Ward Excellence Program","Peking University People's Hospital Scientific Research Development Funds","the Grants from the Beijing Municipal Science and Technology Commission","the Grants from the NSFC"],"pagination":["180"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12839384"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(1)"],"pubmed_abstract":["<b>Background</b>: The International Consensus Classification (ICC) currently proposes an empirical variant allele frequency (VAF) threshold of 10% to define TP53-mutated acute myeloid leukemia (AML) and to distinguish oncogenic driver from concomitant mutations. However, the optimal cutoff remains uncertain, and the biological and clinical features of low-VAF cases have not been systematically characterized. <b>Methods</b>: In this single-center retrospective cohort study, we stratified TP53-mutated AML by a 10% VAF cutoff and compared clinical characteristics, cytogenetic and molecular profiles, and survival outcomes between groups. <b>Results</b>: The VAF < 10% group exhibited a distinctive profile: fewer adverse cytogenetic abnormalities [complex karyotype, -7, -5/del(5q)], a more adve"],"journal":["Biomedicines"],"pubmed_title":["Low-VAF TP53-Mutated AML Displays Distinct Biological Features in a Single-Center Cohort."],"pmcid":["PMC12839384"],"funding_grant_id":["CIFMS, 2023-I2M-C&T-B-123","BRWEP, BRWEP2024W134080100","RDL2023-08","No. 62331025","No. Z221100007422008"],"pubmed_authors":["Zhang K","Lu X","Jiang H","Huang X","Ma X","Wei F","Jiang Q","Zhang S","Chang Y","Zhao X"],"additional_accession":[]},"is_claimable":false,"name":"Low-VAF TP53-Mutated AML Displays Distinct Biological Features in a Single-Center Cohort.","description":"<b>Background</b>: The International Consensus Classification (ICC) currently proposes an empirical variant allele frequency (VAF) threshold of 10% to define TP53-mutated acute myeloid leukemia (AML) and to distinguish oncogenic driver from concomitant mutations. However, the optimal cutoff remains uncertain, and the biological and clinical features of low-VAF cases have not been systematically characterized. <b>Methods</b>: In this single-center retrospective cohort study, we stratified TP53-mutated AML by a 10% VAF cutoff and compared clinical characteristics, cytogenetic and molecular profiles, and survival outcomes between groups. <b>Results</b>: The VAF < 10% group exhibited a distinctive profile: fewer adverse cytogenetic abnormalities [complex karyotype, -7, -5/del(5q)], a more adve","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-09T03:20:05.006Z","creation":"2026-06-09T03:11:58.746Z"},"accession":"S-EPMC12839384","cross_references":{"pubmed":["41595714"],"doi":["10.3390/biomedicines14010180"]}}